🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I am excited to announce that on Monday, I will begin my new journey at Memorial Sloan Kettering Cancer Center, joining Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰, Sohrab Shah, MSK Department of Medicine, The Halvorsen Center for Computational Oncology, and their incredible teams! Grateful for this unique opportunity and their support 🙏🙏! #mmsm #lysm

Our Center recently celebrated its 600th patient treated with CAR T-cell immunotherapy, a groundbreaking “living drug” that utilizes the patient’s immune system to fight cancer. Pioneered at CHOP and Penn Medicine, CAR T has transformed cancer treatment worldwide.

Congratulations, H. Lee Moffitt, 2024 Tampa Metro Civitan Club Outstanding Citizen of the Year Award Recipient. Moffitt Cancer Center

x.com/i/article/1887…

#FollowFriday Meet Hein Liu, MD (Hien D. Liu, MD), a Blood and Marrow Transplant oncologist who specializes in autologous and allogeneic transplants and CAR T-cell therapy. She is the Medical Director of Moffitt’s Apheresis Program and her research focuses on stem cell mobilization

Meet the first patient in the world to receive Tecelra, a groundbreaking engineered cell therapy for synovial #sarcoma. This is a powerful story of resilience and innovation—and I’m so proud of our team Moffitt Cancer Center for leading the way in this area! moffitt.org/endeavor/archi…

Honoring a mentor, and friend Professor f Bipin Savani with ASTCT CoPG Service Award 👏🏻👏🏻👏🏻😍😍😍

Three-year follow-up analysis of first-line axicabtagene ciloleucel in high-risk large B-cell lymphoma (ZUMA-12) ashpublications.org/blood/article/…

Full Ph1 ALPHA/ALPHA2 cema-cel data in Journal of Clinical Oncology, demonstrating long-term durability of a 1x Tx in r/r #LBCL patients with our investigational allogeneic #CART and 100% CR in patients with low disease burden – the focus of our ALPHA3 trial in 1L. $ALLO Frederick L. Locke Learn more

Are you interested in joining the only mathematical oncology department IMO in a cancer center Moffitt Cancer Center in the world? We have an open rank tenure track position (assistant/associate/full) available now and would love to hear from you! Apply here: …cancer-center-careers.hctsportals.com/jobs/1859278-o…

Dr. Sergio Giralt is now giving the Mortimer M. Bortin Lecture, “Something Funny Happened on My Way to Tandem,” in Ballroom B #Tandem25 ASTCT

Interesting, I always wondered why heme biosynthesis comes up as a pathway involved in therapy resistance. Looks like it modulates apoptosis resistance.

Congrats to #dorishansen Krina Patel Surbhi Sidana, MD and the rest of the US myeloma immunotherapy consortium on this excellent #MMsm work, now out in Journal of Clinical Oncology!

Off-the-shelf CAR-T is here! Our phase 1 trial in Journal of Clinical Oncology shows allogeneic CD19 CAR-T cemacabtagene ansegedleucel (cema-cel) delivers durable remissions in R/R DLBCL: 🔹42% CR rate with median CR duration 23.1 months 🔹No GVHD, ICANS, or severe CRS ascopubs.org/doi/10.1200/JC…

Years ago, we decided cell therapies were going to be critical to cancer care and research, and today Moffitt Cancer Center is a leader in the field. It didn’t happen by chance. #ThursdayThoughts ➡️ How are you creating your future?

Advancing CAR T-Cell Therapy - Off-the-Shelf Allogeneic Approach - Yan Leyfman, MD Frederick L. Locke oncodaily.com/science/yan-le… #Cancer #ImmuneOnc #IO #ImmunoOncology #Immunotherapy #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology

Thanks to all my amazing Moffitt Cancer Center collaborators - but special thanks go out to Dietrich Werner Idiaquez for your BEAUTIFUL images of sBCMA expressing myeloma cells that grace the cover of Blood this week

For me, ⁦Marco Ruella⁩ is the best scientist in our field right now. Fantastic to host him ⁦Moffitt Cancer Center⁩ ⁦Frederick L. Locke⁩ today in Tampa

Big News for CAR T cell delivery to patients and monitoring: FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies #FDA #Tcellrx #immunotherapy fda.gov/vaccines-blood…

Join us in congratulating Moffitt Cancer Center President and CEO, Patrick Hwu, MD, for being recognized by his peers and the Tampa Bay Business Journal as one of Tampa Bay’s 2025 Most Admired CEOs. This recognition reflects his leadership in advancing Moffitt as Florida’s